Given that rapamycin is an mTOR inhibitor, this study aims to investigate whether low-dose rapamycin treatment improves autophagy markers and clinical symptoms of fatigue in ME/CFS subjects. This evidence concerns the gene MTOR and myalgic encephalomeyelitis/chronic fatigue syndrome.